Published in Eur J Biochem on May 01, 1998
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol (2007) 3.29
Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol (2003) 1.81
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs (2008) 1.56
Integrin alphavbeta3, requirement for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF. Cell Stress Chaperones (2003) 1.29
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer (2012) 1.21
Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer. Invest New Drugs (2012) 0.96
Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro. Clin Exp Metastasis (2000) 0.87
A phase I study of continuous infusion cilengitide in patients with solid tumors. Invest New Drugs (2010) 0.86
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med (1997) 6.19
The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer (1997) 5.01
Reduction in intraventricular hemorrhage by elimination of fluctuating cerebral blood-flow velocity in preterm infants with respiratory distress syndrome. N Engl J Med (1985) 2.76
Psychopathology associated with suicidal ideation and attempts among children and adolescents. J Am Acad Child Adolesc Psychiatry (1998) 2.46
Cleavage of Chordin by Xolloid metalloprotease suggests a role for proteolytic processing in the regulation of Spemann organizer activity. Cell (1997) 2.44
An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature (1994) 2.41
Young, gifted.and spurned. Nature (2001) 2.13
Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med (1992) 2.12
New advances in the management of acute coronary syndromes: 1. Matching treatment to risk. CMAJ (2001) 2.12
Test-retest reliability of the Diagnostic Interview Schedule for Children (DISC 2.1). Parent, child, and combined algorithms. Arch Gen Psychiatry (1995) 2.05
Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med (1996) 1.99
Specific binding of the human S protein (vitronectin) to streptococci, Staphylococcus aureus, and Escherichia coli. Infect Immun (1987) 1.90
Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem (1988) 1.77
Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. J Clin Oncol (1995) 1.71
Inter-regional differences and outcome in unstable angina; analysis of the international ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events. Eur Heart J (2000) 1.71
Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study. Eur Heart J (2002) 1.65
Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med (1998) 1.57
Time to treatment influences the impact of ST-segment resolution on one-year prognosis: insights from the assessment of the safety and efficacy of a new thrombolytic (ASSENT-2) trial. Circulation (2001) 1.56
Use of synthetic oligoribonucleotides to probe RNA-protein interactions in the MS2 translational operator complex. Nucleic Acids Res (1990) 1.54
Lipodermatosclerosis is characterized by elevated expression and activation of matrix metalloproteinases: implications for venous ulcer formation. J Invest Dermatol (1998) 1.54
Urokinase receptor: a molecular organizer in cellular communication. Curr Opin Cell Biol (2000) 1.52
Efficacy of postoperative blood salvage following total hip arthroplasty in patients with and without deposited autologous units. J Bone Joint Surg Am (2000) 1.51
Primary breast lymphoma with skin involvement arising in lymphocytic lobulitis. Histopathology (1994) 1.45
Expression of the cystic fibrosis gene in human development. Development (1991) 1.45
Canadian Cardiovascular Society Consensus Conference 2002: Management of heart disease in the elderly patient. Can J Cardiol (2004) 1.44
First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. J Thromb Haemost (2005) 1.42
Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res (1997) 1.42
Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut (2002) 1.41
Outer membrane protein YadA of enteropathogenic yersiniae mediates specific binding to cellular but not plasma fibronectin. Infect Immun (1993) 1.41
Combined radiotherapy and medical immunosuppression in the management of thyroid eye disease. Eye (Lond) (1997) 1.41
Europe's Mars mission to pay out for Beagle lander. Nature (2001) 1.38
Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant. J Lab Clin Med (1995) 1.38
Physicochemical characterization of human S-protein and its function in the blood coagulation system. Biochem J (1985) 1.38
PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. Am J Pathol (1999) 1.36
The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res (1996) 1.34
Proteinases in bone resorption: obvious and less obvious roles. Clin Chim Acta (2000) 1.33
Inhibition of C9 polymerization within the SC5b-9 complex of complement by S-protein. Acta Pathol Microbiol Immunol Scand Suppl (1984) 1.32
Mediation of adherence of streptococci to human endothelial cells by complement S protein (vitronectin). Infect Immun (1988) 1.27
The binding protein for globular heads of complement C1q, gC1qR. Functional expression and characterization as a novel vitronectin binding factor. J Biol Chem (1996) 1.27
Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes. Clin Exp Immunol (1988) 1.25
Oxford meniscal bearing knee versus the Marmor knee in unicompartmental arthroplasty for arthrosis. A Swedish multicenter survival study. J Arthroplasty (1995) 1.22
Adverse life events and resilience. J Am Acad Child Adolesc Psychiatry (1998) 1.20
The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett (1997) 1.20
Methodologic pitfalls in the determination of genetic anticipation: the case of Crohn disease. Ann Intern Med (2001) 1.17
RGD peptides and monoclonal antibodies, antagonists of alpha(v)-integrin, enter the cells by independent endocytic pathways. Lab Invest (2001) 1.17
Isolation and characterization of the circulating form of human endostatin. FEBS Lett (1997) 1.16
Relationship between specific adverse life events and psychiatric disorders. J Abnorm Child Psychol (2001) 1.15
Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res (1997) 1.14
Localization of beta 1-integrins in human cartilage and their role in chondrocyte adhesion to collagen and fibronectin. Exp Cell Res (1993) 1.13
In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer (2000) 1.11
The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8, and C9 and perforin from cytolytic T-cells and inhibits their lytic activities. Biochemistry (1988) 1.10
Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex. J Biol Chem (1995) 1.09
Worldwide patterns of mitochondrial DNA differentiation in the harbor seal (Phoca vitulina). Mol Biol Evol (1996) 1.09
HCG in the regulation of placental angiogenesis. Results of an in vitro study. Placenta (2007) 1.08
Management of relapse after allo-SCT for AML and the role of second transplantation. Bone Marrow Transplant (2009) 1.08
Regulation of leukocyte recruitment by polypeptides derived from high molecular weight kininogen. FASEB J (2001) 1.05
Angiogenic capacity of endothelial cells in islets of Langerhans. FASEB J (2003) 1.05
Pulse oximetry is a poor predictor of hypoxemia in stable children with sickle cell disease. Arch Pediatr Adolesc Med (2000) 1.05
Intrauterine diagnosis: potential complications. Am J Obstet Gynecol (1973) 1.04
Factor VII and single-chain plasminogen activator-activating protease: activation and autoactivation of the proenzyme. Eur J Biochem (2001) 1.03
A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides. J Exp Med (1994) 1.02
The effect of a perioperative clinical pathway for knee replacement surgery on hospital costs. Anesth Analg (1998) 1.02
Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders. Arterioscler Thromb Vasc Biol (1997) 1.02
Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina. Lab Invest (1996) 1.02
Endothelin in the gastrointestinal tract. Presence of endothelinlike immunoreactivity, endothelin-1 messenger RNA, endothelin receptors, and pharmacological effect. Gastroenterology (1990) 1.02
Multimeric vitronectin. Identification and characterization of conformation-dependent self-association of the adhesive protein. J Biol Chem (1993) 1.01
Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers. Bone Marrow Transplant (2012) 1.00
The influence of ageing and exercise on tendon growth and degeneration--hypotheses for the initiation and prevention of strain-induced tendinopathies. Comp Biochem Physiol A Mol Integr Physiol (2002) 1.00
Differential modulation of cell adhesion by interaction between adhesive and counter-adhesive proteins: characterization of the binding of vitronectin to osteonectin (BM40, SPARC). Biochem J (1997) 1.00
Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant (1997) 1.00
Registered nurses' experiences with an evidence-based home care pathway for myocardial infarction clients. Can J Cardiovasc Nurs (2004) 0.99
Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions. Blood (2000) 0.99
Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. FEBS Lett (1994) 0.99
Multiple interactions between human vitronectin and Staphylococcus aureus. Biochim Biophys Acta (1993) 0.98
Molecular mechanisms of zinc-dependent leukocyte adhesion involving the urokinase receptor and beta2-integrins. Blood (1999) 0.98
Release of the angiogenesis inhibitor angiostatin in patients with proliferative diabetic retinopathy: association with retinal photocoagulation. Diabetologia (2000) 0.98
S protein modulates the heparin-catalyzed inhibition of thrombin by antithrombin III. Evidence for a direct interaction of S protein with heparin. Eur J Biochem (1986) 0.96
Intermittent micromotion inhibits bone ingrowth. Titanium implants in rabbits. Acta Orthop Scand (1992) 0.96
Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. Am J Cardiol (1998) 0.95
Murine monoclonal antibodies to the myelin-associated glycoprotein react with large granular lymphocytes of human blood. Proc Natl Acad Sci U S A (1985) 0.94
Clustering of vitronectin and RGD peptides on microspheres leads to engagement of integrins on the luminal aspect of endothelial cell membrane. Blood (1994) 0.94
Peptide contents of neuropeptide Y, vasoactive intestinal polypeptide, and beta-calcitonin gene-related peptide and their messenger ribonucleic acids after dexamethasone treatment in the isolated rat islets of Langerhans. Endocrinology (1991) 0.94
Fibronectin, laminin, vitronectin and their receptors at newly-formed capillaries in proliferative diabetic retinopathy. Exp Eye Res (1995) 0.93
Thrombin-induced fibrinopeptide B release from normal and variant fibrinogens: influence of inhibitors of fibrin polymerization. Biochim Biophys Acta (1988) 0.93
Purtscher's-like retinopathy in chronic renal failure. Ophthalmology (1992) 0.93
Novel glycosylated forms of human plasma endostatin and circulating endostatin-related fragments of collagen XV. Biochemistry (1999) 0.93
Combined magnification endoscopy with chromoendoscopy in the evaluation of patients with suspected malabsorption. Gastrointest Endosc (1997) 0.92
The membrane attack complex of complement: relation of C7 to the metastable membrane binding site of the intermediate complex C5b-7. J Immunol (1985) 0.92
Binding of vitronectin-thrombin-antithrombin III complex to human endothelial cells is mediated by the heparin binding site of vitronectin. J Biol Chem (1992) 0.92
Comparison of in vitro and in vivo approaches to studying brain colonization by breast cancer cells. J Neurooncol (2011) 0.91